CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 42 enrolled
Drug / intervention
Renal function +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04940260
NCT04940260N/ACompleted
CompareCT.gov

Long Term Renal Outcome in Preeclampsia : Role of sFlt-1 / PlGF and Endoglin

Bangkok Metropolitan Administration Medical College and Vajira Hospital·observational·Posted Jun 25, 2021·Updated Jun 29, 2021

In Brief

An observational study evaluating Renal function and proteinuria for Preeclampsia and Renal Function. Completed, enrolled 42 participants across 1 site.

Detailed Summary

Preeclampsia (PE) is an important complication of pregnancy and can lead to chronic kidney disease by causing endothelial damage and podocyte loss, Soluble forms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), sFlt1 / PlGF ratio and endoglin are the biomarkers for the differential diagnosis of preeclampsia and other diseases. We aim to explore the correlation of these biomarkers with long term renal function, blood pressure and urine albumin creatinine ratio (UACR) in PE patients.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPreeclampsia, Renal Function
CountriesThailand
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJun 25, 2021
Enrollment StartOct 1, 2019
Primary CompletionDec 15, 2020
Study CompletionJan 31, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 5.0 years ago

Interventions

Renal functionother

measure eGFR at one year post partum

proteinuriaother

measure urine protein creatinine ratio at one year postpartum